PAUL HILL: Open Payments
NPI 1124160742 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$797 in 26 payments from 8 companies in 2025. Trend: 2023 $707 · 2024 $513 · 2025 $797
Food & beverage: $715Education: $82
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 5 | $338 |
| ABBVIE INC. | 11 | $155 |
| Novartis Pharmaceuticals Corporation | 4 | $106 |
| Janssen Biotech, Inc. | 1 | $72 |
| Amgen Inc. | 2 | $49 |
| REVANCE THERAPEUTICS, INC. | 1 | $40 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Galderma Laboratories, L.P. | 1 | $16 |
Products named: Bimzelx, SKYRIZI, COSENTYX, TREMFYA, OTEZLA, DAXXIFY, BOTOX, Sotyktu.
Industry payments across WA — which companies pay providers there.
